GOSS: Gossamer Bio Inc

GOSS新闻

• 19:31 查丹资本开始覆盖 Gossamer Bio，给予买入评级，并宣布目标价为 160 美元
• 19:31 Chardan Capital Initiates Coverage On Gossamer Bio with Buy Rating, Announces Price Target of $160
• 21:05 12 Health Care Stocks Moving In Friday's After-Market Session
• 20:02 Gossamer Bio Submits NDA To FDA For Seralutinib For Treatment Of Pulmonary Arterial Hypertension
• 20:02 Gossamer Bio向FDA提交Seralutinib治疗肺动脉高压的新药申请(NDA)
• 10:27 HC Wainwright & Co.维持对Gossamer Bio的买入评级，将目标股价提高至90美元
• 10:27 HC Wainwright & Co. Maintains Buy on Gossamer Bio, Raises Price Target to $90
• 21:06 12 Health Care Stocks Moving In Friday's After-Market Session
• 21:06 周五盘后交易中涨跌幅较大的12家医疗保健股
• 15:47 Gossamer Bio Slips as $250M Financing Hinges on FDA Approval - Gossamer Bio (NASDAQ:GOSS)
• 21:15 Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates
• 12:25 Pelthos Therapeutics Inc. (PTHS) Reports Q2 Loss, Lags Revenue Estimates
• 21:40 Kura Oncology (KURA) Reports Q2 Loss, Beats Revenue Estimates
• 14:00 Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
• 16:38 Gossamer Bio, Inc. (GOSS) Discusses Reacquisition of Seralutinib Rights, Regulatory Progress and Capital Structure Updates Transcript